Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten in Duchenne Muscular Dystrophy
NCT05540860Phase 2Active, not recruiting
- Start
- Oct 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sevasemten in Duchenne muscular dystrophy (DMD). Started Oct 2022; status: active, not recruiting.
02
Drugs
sevasemten
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05540860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540860.